Electrical field therapy with reduced histopathological change in muscle

• US 7,570,992 B2
• Filed: 01/13/2004
• Issued: 08/04/2009
• Est. Priority Date: 07/13/1998
• Status: Expired due to Term

• Current Assignee: Inovio Pharmaceuticals, Inc.
• Original Assignee: Genetronics, Inc. (Inovio Pharmaceuticals, Inc.)
• Inventors: Nolan, Edward, Zhang, Lei, Rabussay, Dietmar P., Widera, Georg
• Primary Examiner(s): KENNEDY, SHARON E
• Application Number:
  US10/756,946
• Publication Number:
  US 20040147964A1
• Time in Patent Office: 2,030 Days
• Field of Search: 604/20, 604/21, 604/49, 604313-316, 604/501, 606/41, 606/42, 606/44, 606 48- 50, 607/115, 607/120
• US Class Current: 604/21
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428

Abstract

In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Claims

1. A method for delivering a therapeutic agent to a subject, comprising;

introducing an effective amount of at least one therapeutic agent into a target muscle tissue site of a subject, wherein the therapeutic agent comprises a polynucleotide that encodes a therapeutic protein or peptide; and

generating an electric field at the target muscle tissue site by introducing from 1 to about 4 monopolar DC pulses, each pulse having a duration of about 10 ms to about 100 ms, to generate a nominal field strength of about 100 V/cm to about 300 V/cm at the target muscle tissue site.

2. A method according to claim 1, that reduces histopathological change at the target muscle tissue site as a result of the application of the electric field.

3. A method according to claim 2, wherein the histopathological change is selected from the group consisting of inflammation, induction or amplification of an immune response, necrosis, and fibrosis.

4. A method according to claim 1, wherein the duration of each pulse is in the range from about 20 ms to about 60 ms.

5. A method according to claim 1, wherein there are no more than two pulses at each target muscle tissue site.

6. A method according to claim 1, wherein the nominal field strength is in the range from about 100 V/cm to about 232 V/cm.

7. A method according to claim 6, wherein the nominal field strength is in the range from about 100 V/cm to about 150 V/cm.

8. A method according to claim 6, wherein the duration of each pulse is in the range from about 40 ms to about 60 ms.

9. A method according to claim 1, wherein the electric field is generated by applying electroporation electrodes to the subject, wherein a portion of the electrodes that contact the subject is made of a non-toxic, biocompatible metal.

10. A method according to claim 9, wherein the metal is gold.

11. A method according to claim 1, wherein the subject is a mammal.

12. A method according to claim 1, wherein the subject is a human.

13. An in viva method for expressing a therapeutic polypeptide or peptide encoded by an isolated polynucleotide delivered into cells in a subject, comprising;

a) introducing at least one isolated polynucleotide encoding a therapeutic polypeptide or peptide into a target muscle tissue site of a subject; and

b) generating an electric field a the target muscle tissue site by introducing from 1 to about 4 monopolar DC pulses, each having a pulse duration of about 10 to about 100 ms, to generate a nominal field strength of about 100 V/cm to about 300 V/cm at the target muscle tissue site.

14. A method according to claim 13, that reduces histopathological change at the target muscle tissue site as a result of the application of the electric field.

15. A method according to claim 14, wherein the histopathological change is selected from the group consisting of inflammation, induction or amplification of an immune response, necrosis, and fibrosis.

16. A method according to claim 13, wherein the duration is in the range selected from the group consisting of from about 20 ms to about 60 ms and from about 40 ms to about 60 ms.

17. A method according to claim 13, wherein there are no more than two pulses.

18. A method according to claim 13, wherein the nominal field strength is in the range from about 100 V to about 150 V.

19. A method according to claim 13, wherein the polynucleotide is introduced at substantially the same time as generating the electric field.

20. A method according to claim 13, wherein the electric field is generated by applying to the subject electroporation electrodes, wherein a portion of the electrodes that contact the subject is made of a non-toxic, biocompatible metal.

21. A method according to claim 20, wherein the metal is gold.

22. A method according to claim 13, wherein the subject is a mammal.

23. A method according to claim 13, wherein the subject is a human.

24. A method according to claim 13, wherein the polynucleotide is injected intramuscularly at from 1 to about 20 sites in the target muscle tissue.

25. A method according to claim 13, wherein said polynucleotide is selected from the group consisting of double stranded DNA, single-stranded DNA, complexed DNA, formulated DNA, encapsulated DNA, naked RNA, encapsulated RNA and combinations thereof.

26. A method according to claim 13, wherein the polynucleotide encoding the therapeutic polynucleotide is contained in a DNA vector.

27. A method according to claim 13, said polynucleotide being operably associated with a regulatory sequence far expression of the therapeutic polypeptide or peptide in said cells.

28. A method according to claim 13, wherein said polynucleotide further encodes a selectable marker polypeptide.

29. A method according to claim 27, wherein said regulatory sequence comprises a promoter.

30. A method according to claim 29, wherein said promoter is muscle specific.

31. A method according to claim 30, wherein said promoter is a promoter selected from the group consisting of a CMV promoter, a RSV LTR, a MPSV LTR, and a SV40promoter.

32. A method according to claim 13, wherein the electric pulses are administered to the target muscle tissue using an electroporation electrode comprising a plurality of electrically conducting needles.

33. A method according to claim 32, wherein a portion of the needles that contacts the subject is made of a non-toxic, biocompatible metal.

34. A method according to claim 33, wherein the metal is gold.

35. A method for delivering a polynucleotide encoding a peptide or polypeptide to a target muscle tissue site, comprising:

a) introducing an effective amount of at least one isolated polynucleotide encoding a peptide or polypeptide into a target muscle tissue site of a subject;

b) introducing at least a conductive portion of an electrode needle array into the target muscle tissue; and

c) applying from 1 to about 4 monopolar DC pulses having a duration of about 10 ins to about 100 ms each to generate a nominal field strength of about 100 V/cm to about 300 V/cm at the target muscle site, thereby delivering the polynucleotide to the target muscle tissue site.

36. A method according to claim 35, wherein the electrode needle array comprises four electrode needles and two pulses are applied to the target muscle tissue site to generate a nominal field strength of about 116 V/cm.